Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Durham, North Carolina 27710


Genes expressing inflammatory cytokines (TNF- alpha, IL1 etc) and genes involved in apoptosis (Caspase 3, Bax, Bcl-2, Fas) are dysregulated in the skeletal muscles of the patients who have muscle wasting and decreased exercise capacity with CHF. Patients who show benefit from CRT may also show reversal of the inflammatory/apoptotic cascade that accompanies CHF and these patients may be the ones who benefit the most from CRT

Study summary:

1. The general objective of this study is to: 1. To identify the molecular pathways that may be altered in the blood and skeletal muscles of the patients undergoing CRT by using transcriptional analysis of the blood and skeletal muscle in these patients 2. To identify objective measurable molecular signals, using gene expression profiling, that correlate with clinical improvement in patients undergoing CRT. 3. To identify the molecular profile of patients who are most likely to benefit from CRT with improvement of exercise capacity and reversal of cardiac cachexia. 4. To identify biochemical pathways involved in cardiac cachexia. 5. To identify genes involved in positive remodeling and reversal of apoptotic cascade in the skeletal muscle.


Inclusion Criteria: - Patients with poor LV function and an EF of ≤35% - Patients who are symptomatic with Class II or Class III heart failure on optimal medical therapy. - Patients with EKG showing QRS duration of greater than 120 ms and meet criteria for Bi-ventricular ICD implantation. Exclusion Criteria: - Patients with other co-morbid conditions which could contribute to cachexia, such as end stage renal disease, ongoing malignancy, chronic or acute liver failure, age greater than 80yrs. - Patients who are unable to walk and are wheelchair bound or need assistance to walk for reasons other than CHF. - Patients with muscular dystrophies and myopathies. - Patients with untreated hyper or hypothyroidism. - Patients on Dialysis. - Patients with recent (<12 weeks) revascularization. - Patients with recent (<12 weeks) myocardial infarction.



Primary Contact:

Principal Investigator
Patrick Hranitzky, MD
Duke University

Backup Contact:


Location Contact:

Durham, North Carolina 27710
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.